Efficacy of olanzapine: an overview of pivotal clinical trials.
Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepine class. Its relatively greater binding affinity for 5-HT2 compared to D2 receptors makes it similar to the atypical agent clozapine, a serotonin/dopamine antagonist. Four double-blind pivotal studies, which compare olanzapine to placebo and/or haloperidol, are presented. The results suggest that olanzapine is as effective as haloperidol for positive symptoms and more effective than haloperidol for the treatment of the negative symptoms of schizophrenia.
Beasley
C M
CM
Psychopharmacology Division, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Tollefson
G D
GD
Tran
P V
PV
D000208:Acute Disease; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D004311:Double-Blind Method; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D010919:Placebos; D001569:Benzodiazepines; D010890:Pirenzepine; D006220:Haloperidol; D000077152:Olanzapine